Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 7/20 | 0.55 |
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | KDM1A | O60341 | 5/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285030 | 0.87 | ALDH1A1 (0.52) | MAOAMAOBMAPTSMN1; SMN2L3MBTL1 | |
| SCHEMBL13907558 | 0.84 | PDCD1 (0.50) | MAOAMAOBRAB9ANPC1MAPT | |
| SCHEMBL24191358 | 0.83 | KDM1A (0.46) | MAOAMAOBKDM1ATHRATHRB | |
| SCHEMBL2304623 | 0.83 | KDM1A (0.46) | MAOAMAOBKDM1ATHRATHRB | |
| SCHEMBL13907556 | 0.81 | ERN1 (0.51) | MAOAMAOBCCNB2CDK1CDK4 | |
| SCHEMBL16626992 | 0.81 | ALDH1A1 (0.43) | MAOAMAOBRAB9ALMNAHPGD | |
| SCHEMBL4045055 | 0.81 | MAOA (0.57) | MAOAMAOBCCNB2CDK1CDK4 | |
| SCHEMBL8567016 | 0.81 | MAOA (0.45) | MAOAMAOBKDM1ACCNB2CDK1 | |
| SCHEMBL1463088 | 0.81 | ALDH1A1 (0.57) | MAOAMAOBCCNB2CDK1CDK4 | |
| SCHEMBL25367135 | 0.81 | MAOA (0.45) | MAOAMAOBKDM1ACCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106061943-B | It can be used as the bicyclic pyrrole derivatives of the agonist of GPR120 | 詹森药业有限公司 | 2019-11-05 | — | — | CN | disclosed |
| EP-2914580-B1 | THIOARYL DERIVATIVES AS GPR120 AGONISTS | LG CHEMICAL LTD (KR) | 2019-02-20 | — | — | EP | disclosed |
| EP-3114111-B1 | BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-3114111-B1 | BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-09 | — | — | EP | disclosed |
| EP-2970182-B1 | BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-03 | — | — | EP | disclosed |
| EP-2970182-B1 | BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-03 | — | — | EP | disclosed |
| EP-3114111-A1 | BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica NV (BE) | 2017-01-11 | — | — | EP | disclosed |
| CN-106061943-A | Bicyclic pyrrole derivatives useful as agonists of GPR120 | 詹森药业有限公司 | 2016-10-26 | — | — | CN | disclosed |
| US-9447044-B2 | Thioaryl derivatives as GPR120 agonists | LG LIFE SCIENCES LTD. (KR) | 2016-09-20 | — | — | US | disclosed |
| EP-2970182-A1 | BICYCLIC PYRROLE DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica, N.V. (BE) | 2016-01-20 | — | — | EP | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010048207-A2 | ARYL GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
| EP-1537091-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-06-08 | — | — | EP | disclosed |
| US-6809110-B2 | NONINSULIN DEPENDENT DIABETES; SUCH AS 2-ETHOXY-3-(4-(2-(5-METHYL-2-PHENYL-THIAZOL-4-YL)-ETHOXY)-BENZO(B)THIOPHEN-7-YL)-PROPIONIC ACID | HOFFMANN-LA ROCHE INC. | 2004-10-26 | — | — | US | disclosed |
| US-20040110807-A1 | Thiazole derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
| WO-2004020420-A1 | NOVEL 2-ARYLTHIAZOLE COMPOUNDS AS PPARALPHA AND PPARGAMA AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| EP-0325245-B1 | Phenoxyacetic acid derivatives, preparation thereof, pharmaceutical compositions comprising them and use | TANABE SEIYAKU CO (JP) | 1993-10-20 | — | — | EP | disclosed |
| US-4948810-A | PLATELET AGGREGATION INHIBITORS | TANABE SEIYAKU CO., LTD. (JP) | 1990-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | MAOA 3950/4885MAOB 3960/4885KDM1A 4555/4885 |
| US-20040110807-A1 | Thiazole derivatives | SLC5A1, GPR119, INSR | MAOA 4312/4885MAOB 4027/4885KDM1A 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.